Vitae Pharmaceuticals (NASDAQ: VTAE) 54% LOWER; reported Q4 EPS of ($0.52), $0.10 better than the analyst estimate of ($0.62). Revenue ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Jefferies Cuts Price Target on Staples (SPLS) Following 4Q Miss and Soft Guidance March 7, 2016 7:30 AM Chardan Capital Markets Cuts Price target on Ambarella (AMBA) to $50 as Growth Continues to Slow March 7, 2016 6:44 AM Canaccord Genuity Reiterates Buy as Broadcom Ltd. (AVGO) Reports Positive 1Q and Guidance March 4, 2016 10:59 AM Deutsche Bank Reiterates Buy as Hewlett Packard Enterprise (HPE) Reports In-Line 1Q March 4, 2016 10:01 AM